Evidence map›Paper›PMID 40874127›Full record

ReviewFrontiers in neurology2025

Heterozygosity in NPC may be associated with neurologic and systemic phenotypes.

Tatiana Brémovà-Ertl, Sabina Tahirovic, Silva Katušić Hećimović, Kyriakos Martakis, Marianne Rohrbach, Matthias Gautschi, Radhika Dhamija, Jaya Ganesh, Melinda Peters, Mark Walterfang and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tatiana Brémovà-ErtlDepartment of Neurology, Department of Neuropediatrics and Center for Rare Diseases, University Hospital Inselspital, Bern, Switzerland.
Sabina TahirovicGerman Center for Neurodegenerative Diseases (DZNE) e.V., Munich, Munich, Germany.
Silva Katušić HećimovićDivision of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia.
Kyriakos MartakisKlinik für Neuropädiatrie, Epileptologie und Sozialpädiatrie der Justus-Liebig Universität Giessen und des Universitätsklinikums Gießen-Marburg, Giessen, Germany.
Marianne RohrbachReferenzzentrum hereditärer Stoffwechselstörungen, Universitäts-Kinderspital Zürich, Zürich, Switzerland.
Matthias GautschiSwiss Reference Centre for Inborn Errors of Metabolism, Site Bern, INSELSPITAL, Department of Paediatrics, Division of Paediatric Endocrinology, Diabetology and Metabolism, University Hospital Bern, Julie-von-Jenner Haus, Bern, Switzerland.
Radhika DhamijaDepartments of Clinical Genomics and Neurology, Mayo Clinic Rochester, Rochester, MN, United States.
Jaya GaneshDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Melinda PetersDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA, United States.
Mark WalterfangDepartment of Psychiatry, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Susanne A SchneiderINSPIRE-PNRM+, Neuroimaging Center (NIC), University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Niemann-Pick disease type C (NPC) is a pan-ethnic, progressive, recessively inherited lysosomal disorder that affects 1:100,000 live births. Emerging biochemical, genetic, and clinical evidence challenges the traditional view that disease-associated variants in the genes associated with the typical phenotype NPC manifest as an exclusively autosomal recessive disorder. While biallelic pathogenic variants cause the NPC disease phenotype, heterozygous carriers may exhibit phenotypic traits attributable to a partial loss of Methods: We conducted a literature search of articles relevant to heterozygosity in NPC genes and genes associated with other lysosomal diseases. A narrative mini-review format was employed with the intention of providing a brief overview of the frequency of NPC carriers, as well as the biochemical, genetic, non-clinical, and clinical evidence available for readers seeking to understand the scientific basis for why NPC heterozygosity should be discussed and considered as a potential risk factor for the development of neurological phenotype or neurodegenerative diseases. Conclusion: Heterozygosity for many genes, including

Indexed as

carrierheterozygosityheterozygoteNiemann-Pick disease type Crare disease

Identifiers

PMID40874127
PMCPMC12378043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.